A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata

Trial Profile

A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2018

At a glance

  • Drugs ATI 502 (Primary)
  • Indications Alopecia areata
  • Focus Therapeutic Use
  • Sponsors Aclaris Therapeutics
  • Most Recent Events

    • 03 Aug 2018 According to an Aclaris Therapeutics media release, data from this trial is expected in the first half of 2019.
    • 17 May 2018 Planned End Date changed from 18 May 2018 to 18 Jan 2019.
    • 17 May 2018 Planned primary completion date changed from 18 May 2018 to 18 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top